]>
IRCT20190107042281N1 IRCT 2019-08-20 Arak University of Medical Sciences Evaluation of the effect of oral Allopurinol on liver function test in childhood leukemia in maintenance therapy phase Evaluation of the effect of oral Allopurinol on liver function test in childhood leukemia in maintenance therapy phase 2019-06-01 anticipated 40 Complete https://irct.ir/trial/36788 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Systematic codes so that the eligible patients will be coded according to their entrance, meanwhile patients with odd codes will be categorized in control group and who with even codes will be categorized in Intervention group. 3 Acute lymphoblastic leukemia. Intervention 1: Intervention group: Allopurinol tablet receive 4 mg /kg/ day and up to 200 mg daily, divided into two doses. Intervention 2: Control group: There is no intervention. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No more information
public Roya Shaykh Baygloo
Arak Amirkabir Hospital, Parastar Square, Shahid Shiroodi Street
Arak Iran (Islamic Republic of) 3819691187 +98 863313471519 royashb@yahoo.com Arak University of Medical Sciences scientific Aziz Eghbali
Arak Amirkabir Hospital, Parastar Square., Shahid Shiroodi Street
Arak Iran (Islamic Republic of) 3819691187 +98 86 3313 4715 aziz_eghbali@yahoo.com Arak University of Medical Sciences Iran (Islamic Republic of) Children with acute lymphocytic leukemia treated with mercaptopurine 2 years 15 years Both Parental dissatisfaction Renal failure Hepatitis B Hepatitis C AIDS C91.0 Acute lymphoblastic leukemia [ALL] Prevention N/A Intervention group: Allopurinol tablet receive 4 mg /kg/ day and up to 200 mg daily, divided into two doses. Control group: There is no intervention Alanine Aminotransferase. Timepoint: Measurement of serum Alanine Aminotransferase (ALT) levels At the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of allopurinol administration. Method of measurement: blood test. Aspartate Aminotransferase. Timepoint: Measurement of serum Aspartate Aminotransferase (AST) levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of allopurinol administration. Method of measurement: blood test. Alkaline Phosphatase. Timepoint: Measurement of serum Alkaline Phosphatase (ALP) levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of allopurinol administration. Method of measurement: blood test. Total Bilirubin. Timepoint: Measurement of serum Total Bilirubin levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of allopurinol administration. Method of measurement: blood test. Direct Bilirubin. Timepoint: Measurement of serum Direct Bilirubin levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of allopurinol administration. Method of measurement: blood test. Arak University of Medical Sciences Approved 2018-11-04 Ethics committee of Arak University of Medical Sciences Arak university of madical science., Basij square., Sardasht., Arak Arak Markazi Iran (Islamic Republic of)